teclistamab + daratumumab + pomalidomide

This is a **triple drug combination** of teclistamab, daratumumab, and pomalidomide, evaluated primarily for the treatment of relapsed/refractory multiple myeloma. - **Teclistamab** is a bispecific monoclonal antibody that targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, redirecting T cells to kill myeloma cells. - **Daratumumab** is a monoclonal antibody targeting CD38, highly expressed on myeloma cells, inducing tumor cell death by direct cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and modulation of the immune milieu. - **Pomalidomide** is an immunomodulatory drug (IMiD) that augments immune effector function, enhances T cell and natural killer (NK) cell activity, and has anti-angiogenic and direct antitumor effects. The combination is being studied in patients with relapsed/refractory multiple myeloma and has shown promising efficacy in phase 1b clinical trials (MajesTEC-2 and TRIMM-2), especially in heavily pretreated populations.

Other names

teclistamab-cqyv + daratumumab + pomalidomideTecvayli + Darzalex + Pomalyst